The Multiple-Input Multiple-Output(MIMO)Non-Orthogonal Multiple Access(NOMA)based on Spatial Modulation(SM-MIMO-NOMA)system has been proposed to achieve better spectral efficiency with reduced radio frequency chains c...The Multiple-Input Multiple-Output(MIMO)Non-Orthogonal Multiple Access(NOMA)based on Spatial Modulation(SM-MIMO-NOMA)system has been proposed to achieve better spectral efficiency with reduced radio frequency chains comparing to the traditional MIMO-NOMA system.To improve the performance of SM-MIMO-NOMA systems,we extend them to generalized spatial modulation scenarios while maintaining moderate complexity and fairness.In this paper,system spectral efficiency and transmission quality improvements are proposed by investigating a sum-rate maximization resource allocation problem that is subject to the total transmitted power,user grouping,and resource block constraints.To solve this non-convex and difficult problem,a graph-based user grouping strategy is proposed initially to maximize the mutual gains of intragroup users.An auxiliary-variable approach is then adopted to transform the power allocation subproblem into a convex one.Simulation results demonstrate that the proposed algorithm has better performance in terms of bit error rate and sum rates.展开更多
To the Editor:Spondyloarthritis(SpA)is the umbrella term for a broad spectrum of inflammatory rheumatic diseases with different clinical manifestations and characteristic imaging features.Furthermore,enthesitis is con...To the Editor:Spondyloarthritis(SpA)is the umbrella term for a broad spectrum of inflammatory rheumatic diseases with different clinical manifestations and characteristic imaging features.Furthermore,enthesitis is considered a pathological,clinical,and imaginable hallmark of the SpA.In addition to ineffective clinical evaluation techniques of enthesitis,there are useful imaging methods to assess enthesitis,such as whole-body magnetic resonance imaging[1]and ultrasound(US)[2]examination.US has the advantage of real-time imaging and high-cost effectiveness performance.The difference in enthesitis detected by US between non-radiographic-axial SpA(nr-axSpA)and radiographic-axSpA/ankylosing spondylitis(AS)has been seldom researched.Recently,we compared the prevalence and severity of enthesitis between nr-axSpA and AS.展开更多
Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 rep...Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication.Meplazumab is a humanized anti-CD147 IgG_(2) monoclonal antibody,which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019(COVID-19)patients.Here,we conducted a randomized,double-blinded,placebo-controlled phase 1 trial to evaluate the safety,tolerability,and pharmacokinetics of meplazumab in healthy subjects,and an open-labeled,concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 patients.In phase 1 study,59 subjects were enrolled and assigned to eight cohorts,and no serious treatment-emergent adverse event(TEAE)or TEAE grade≥3 was observed.The serum and peripheral blood Cmax and area under the curve showed non-linear pharmacokinetic characteristics.No obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each cohort.The biodistribution study indicated that meplazumab reached lung tissue and maintained>14 days stable with the lung tissue/cardiac blood-pool ratio ranging from 0.41 to 0.32.In the exploratory phase 2 study,17 COVID-19 patients were enrolled,and 11 hospitalized patients were involved as concurrent control.The meplazumab treatment significantly improved the discharged(P=0.005)and case severity(P=0.021),and reduced the time to virus negative(P=0.045)in comparison to the control group.These results show a sound safety and tolerance of meplazumab in healthy volunteers and suggest that meplazumab could accelerate the recovery of patients from COVID-19 pneumonia with a favorable safety profile.展开更多
基金supported by the National Key Research and Development Program of China(Grant No.2019YFC1511300)the National Natural Science Foundation of China(Grant No.U21A20447 and 61971079)+2 种基金the Basic Research and Frontier Exploration Project of Chongqing (Grant No.cstc2019jcyj-msxmX0666)the Innovative Group Project of the National Natural Science Foundation of Chongqing (Grant No.cstc2020jcyj-cxttX0002)the Regional Creative Cooperation Program of Sichuan (2020YFQ0025).
文摘The Multiple-Input Multiple-Output(MIMO)Non-Orthogonal Multiple Access(NOMA)based on Spatial Modulation(SM-MIMO-NOMA)system has been proposed to achieve better spectral efficiency with reduced radio frequency chains comparing to the traditional MIMO-NOMA system.To improve the performance of SM-MIMO-NOMA systems,we extend them to generalized spatial modulation scenarios while maintaining moderate complexity and fairness.In this paper,system spectral efficiency and transmission quality improvements are proposed by investigating a sum-rate maximization resource allocation problem that is subject to the total transmitted power,user grouping,and resource block constraints.To solve this non-convex and difficult problem,a graph-based user grouping strategy is proposed initially to maximize the mutual gains of intragroup users.An auxiliary-variable approach is then adopted to transform the power allocation subproblem into a convex one.Simulation results demonstrate that the proposed algorithm has better performance in terms of bit error rate and sum rates.
文摘To the Editor:Spondyloarthritis(SpA)is the umbrella term for a broad spectrum of inflammatory rheumatic diseases with different clinical manifestations and characteristic imaging features.Furthermore,enthesitis is considered a pathological,clinical,and imaginable hallmark of the SpA.In addition to ineffective clinical evaluation techniques of enthesitis,there are useful imaging methods to assess enthesitis,such as whole-body magnetic resonance imaging[1]and ultrasound(US)[2]examination.US has the advantage of real-time imaging and high-cost effectiveness performance.The difference in enthesitis detected by US between non-radiographic-axial SpA(nr-axSpA)and radiographic-axSpA/ankylosing spondylitis(AS)has been seldom researched.Recently,we compared the prevalence and severity of enthesitis between nr-axSpA and AS.
基金the China National Science and Technology Major Project(2019ZX09732-001).
文摘Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication.Meplazumab is a humanized anti-CD147 IgG_(2) monoclonal antibody,which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019(COVID-19)patients.Here,we conducted a randomized,double-blinded,placebo-controlled phase 1 trial to evaluate the safety,tolerability,and pharmacokinetics of meplazumab in healthy subjects,and an open-labeled,concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 patients.In phase 1 study,59 subjects were enrolled and assigned to eight cohorts,and no serious treatment-emergent adverse event(TEAE)or TEAE grade≥3 was observed.The serum and peripheral blood Cmax and area under the curve showed non-linear pharmacokinetic characteristics.No obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each cohort.The biodistribution study indicated that meplazumab reached lung tissue and maintained>14 days stable with the lung tissue/cardiac blood-pool ratio ranging from 0.41 to 0.32.In the exploratory phase 2 study,17 COVID-19 patients were enrolled,and 11 hospitalized patients were involved as concurrent control.The meplazumab treatment significantly improved the discharged(P=0.005)and case severity(P=0.021),and reduced the time to virus negative(P=0.045)in comparison to the control group.These results show a sound safety and tolerance of meplazumab in healthy volunteers and suggest that meplazumab could accelerate the recovery of patients from COVID-19 pneumonia with a favorable safety profile.
